Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens–Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad234 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Ying-Ming Chiu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Immunology, and Rheumatology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Stevens-Johnson Syndrome. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Taiwan University Hospital, Hsin-Chu branch, Ministry of Science and Technology of Taiwan.
Abstract (Originalsprache)
Background
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) not only cause acute, devastating mucocutaneous reactions but also have long-lasting implications on survivors’ lives.
Objectives
To quantify the lifetime burden of SJS/TEN.
Methods
The cumulative incidence rate (CIR), life expectancy (LE), loss-of-life expectancy (LoLE) and lifetime healthcare expenditure (HE) for SJS/TEN were estimated over the period from 2008 to 2019 using data from the National Health Insurance Research Database of Taiwan and life tables of vital statistics.
Results
In this nationwide cohort of 6552 incident SJS/TEN cases, a trend towards a decrease in the CIR was observed between 2008 and 2019. Compared with the general population, patients with SJS/TEN experience a tremendous loss of 9.43 (1.06) [mean (SEM)] years of LE after diagnosis of SJS/TEN. Male patients with SJS/TEN had higher LoLE [10.74 (1.22) vs. 7.69 (1.43) years] and annual HE than females. Younger age at diagnosis of SJS/TEN was associated with longer LE but greater LoLE and higher lifetime HE. Patients with intensive care unit admission on diagnosis, malignancy, diabetes mellitus, end-stage renal disease and SJS/TEN-associated sequelae experienced substantially greater LoLE and HE per life year.
Conclusions
Patients with SJS/TEN suffer substantial loss-of-LE and HE, particularly young patients, compared with the general population. These data provide a reference estimate of the lifetime burden of SJS/TEN to help health authorities evaluate the cost-effectiveness of future preventive and treatment strategies to minimize the burden of SJS/TEN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Allergy, Immunology, and Rheumatology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
- Department of Nursing, Jen Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- Department of Dermatology, National Taiwan University Hsin-Chu Hospital, Hsinchu, Taiwan.
- Department of Dermatology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
- Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan.
Förderung
- National Taiwan University Hospital, Hsin-Chu branch
- Ministry of Science and Technology of Taiwan
Zitieren
APA
Chiu, Y. M., & Chiu, H. Y. (2023). Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens–Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad234
Vancouver
Chiu YM, Chiu HY. Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens–Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad234
BibTeX
@article{Chiu2023,
author = {Chiu, Ying-Ming and Chiu, Hsien-Yi},
title = {Lifetime risk, life expectancy, loss-of-life expectancy and lifetime healthcare expenditure for Stevens–Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad234}
}
EUVIMED